These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33185320)

  • 1. Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis.
    Pedersen MR; Greenan G; Arora S; Murali AR; Mayo MJ
    Liver Transpl; 2021 Jun; 27(6):866-875. PubMed ID: 33185320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.
    Montano-Loza AJ; Lytvyak E; Hirschfield G; Hansen BE; Ebadi M; Berney T; Toso C; Magini G; Villamil A; Nevens F; Van den Ende N; Pares A; Ruiz P; Terrabuio D; Trivedi PJ; Abbas N; Donato MF; Yu L; Landis C; Dumortier J; Dyson JK; van der Meer AJ; de Veer R; Pedersen M; Mayo M; Manns MP; Taubert R; Kirchner T; Belli LS; Mazzarelli C; Stirnimann G; Floreani A; Cazzagon N; Russo FP; Burra P; Zigmound U; Houri I; Carbone M; Mulinacci G; Fagiuoli S; Pratt DS; Bonder A; Schiano TD; Haydel B; Lohse A; Schramm C; Rüther D; Casu S; Verhelst X; Beretta-Piccoli BT; Robles M; Mason AL; Corpechot C;
    J Hepatol; 2024 Oct; 81(4):679-689. PubMed ID: 38821360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients.
    Mijic M; Saric I; Delija B; Lalovac M; Sobocan N; Radetic E; Martincevic D; Filipec Kanizaj T
    Can J Gastroenterol Hepatol; 2022; 2022():7831165. PubMed ID: 35910038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary biliary cirrhosis in the era of liver transplantation.
    Raczyńska J; Habior A; Pączek L; Foroncewicz B; Pawełas A; Mucha K
    Ann Transplant; 2014 Sep; 19():488-93. PubMed ID: 25262831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    Bosch A; Dumortier J; Maucort-Boulch D; Scoazec JY; Wendum D; Conti F; Morard I; Rubbia-Brandt L; Terris B; Radenne S; Abenavoli L; Poupon R; Chazouillères O; Calmus Y; Boillot O; Giostra E; Corpechot C
    J Hepatol; 2015 Dec; 63(6):1449-58. PubMed ID: 26282232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for recurrent primary biliary cirrhosis after liver transplantation: A systematic review and meta-analysis.
    Li X; Peng J; Ouyang R; Yang Y; Yu C; Lin H
    Dig Liver Dis; 2021 Mar; 53(3):309-317. PubMed ID: 33380381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Transplantation for Primary Biliary Cholangitis.
    Martin EF
    Clin Liver Dis; 2022 Nov; 26(4):765-781. PubMed ID: 36270728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, November 2020.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101679. PubMed ID: 33727161
    [No Abstract]   [Full Text] [Related]  

  • 14. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
    John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
    Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid for primary biliary cirrhosis.
    Gong Y; Huang ZB; Christensen E; Gluud C
    Cochrane Database Syst Rev; 2008 Jul; (3):CD000551. PubMed ID: 18677775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.
    de Veer RC; van Hooff MC; Corpechot C; Thorburn D; Invernizzi P; Lammers WJ; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Parés A; Mason AL; Kowdley KV; Trivedi PJ; Hirschfield GM; Goet JC; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Hansen BE; Harms MH; van der Meer AJ;
    Am J Gastroenterol; 2023 Jul; 118(7):1196-1203. PubMed ID: 36621963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.
    de Veer RC; Harms MH; Corpechot C; Thorburn D; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Parés A; Mason AL; Kowdley KV; Trivedi PJ; Hirschfield GM; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lammers WJ; Hansen BE; van Buuren HR; van der Meer AJ;
    Aliment Pharmacol Ther; 2022 Nov; 56(9):1408-1418. PubMed ID: 36138566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.